Results 101 to 110 of about 5,418,708 (164)

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort

Cancer Science, Volume 117, Issue 10, Page 2819-2826, October 2026.
Off‐label nivolumab treatment guided by CGP results was evaluated in 56 patients with advanced solid tumors. TMB‐High was the predominant biomarker leading to nivolumab treatment. Nivolumab showed limited clinical benefit in 50 patients with measurable disease, with an ORR of 16.0%, DCR of 40.0%, median PFS of 2.7 months, and median OS of 7.2 months ...
Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, Satoshi Nishiwaki, Ichiro Kinoshita, Tetsuhiro Yoshinami, Chigusa Morizane, Yusuke Sato, Toshio Kubo, Mamoru Ito, Hiroshi Nishihara, Toru Mukohara, Hidekazu Shirota, Ryo Ko, Taro Shibata, Manabu Muto, Noboru Yamamoto   +16 more
wiley   +1 more source

Journey through the Decades: The Evolution in Treatment and Shared Decision Making for Locally Advanced Rectal Cancer

The management of locally advanced rectal cancer has undergone significant transformations over the decades and optimal treatment approaches continue to evolve.
Jonathan S. Abelson, Racquel S. Gaetani, Keren Ladin   +2 more
core   +1 more source

Systemic inflammation and prognosis in patients with RAS/BRAF wild‐type metastatic colorectal cancer receiving anti‐EGFR therapy: A real‐world cohort study

Colorectal Disease, Volume 28, Issue 10, October 2026.
Abstract Aim Colorectal cancer outcomes are heterogeneous, so greater prognostic discrimination is needed. In this retrospective real‐world analysis, we assessed the prognostic effect of markers of systemic inflammation in a cohort of patients with RAS/BRAF wild‐type metastatic colorectal cancer (mCRC) who received anti‐EGFR therapy during routine care.
Jordan W. Appleyard, Faye Elliott, Nancy L. Sapanara, Liping Zhang, Uday Kurkure, Jenny F. Seligmann, Nicholas P. West, Kandavel Shanmugam, Philip Quirke, Christopher J. M. Williams, on behalf of the N6 Collaboration   +10 more
wiley   +1 more source

A rectal cancer organoid platform to study individual responses to chemoradiation

, 2019
Rectal cancer (RC) is a challenging disease to treat that requires chemotherapy, radiation and surgery to optimize outcomes for individual patients. No accurate model of RC exists to answer fundamental research questions relevant to patients.
Rectal cancer organoid platform
core  

Locally advanced rectal cancer : aspects on management, outcome and quality of life [Elektronisk resurs]

, 2009
Rectal cancer is common in Sweden, with about 1650 patients diagnosed annually. In 10-15% of the patients the tumour is locally advanced at diagnosis, i.e. the cancer is growing outside the mesorectal fascia, into adjacent organs in the pelvis.
Jansson, Palmer G,
core  

The effect of health care expenditures on survival in locally advanced and metastatic Non Small Cell Lung Cancer [PDF]

Context: The significant survival benefit of chemotherapy over best supportive care for locally advanced and metastatic NSCLC has been amply demonstrated in the literature.
Paul Rebattu, Lionel Perrier, Frédéric Gomez, Marie-Odile Carrère, Magali Morelle, Nathalie Havet, Bertrand Favier, Anthony Montella, David Pérol   +8 more
core  

Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer. [PDF]

Cancer Med
Udagawa S, Osumi H, Taguchi S, Noguchi T, Sakamoto T, Matsui S, Mukai T, Yamaguchi T, Fukuoka S, Yoshino K, Shimozaki K, Wakatsuki T, Ogura M, Ooki A, Chin K, Yamaguchi K, Akiyoshi T, Shinozaki E.   +17 more
europepmc   +1 more source

Influence of KRAS mutation subtypes on response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: meta-analysis. [PDF]

BJS Open
Sadien ID, Cooper G, Phillips V, Joshi H, Wheeler J, Davies RJ.   +5 more
europepmc   +1 more source

A simple MRI/PET-derived index predicts relapse-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. [PDF]

Colorectal Dis
Shioi I, Shiraishi T, Uehara K, Shimizu Y, Hosoi N, Dorjkhorloo G, Katayama C, Shibasaki Y, Komine C, Okada T, Kimura A, Sano A, Yokobori T, Sakai M, Shirabe K, Saeki H.   +15 more
europepmc   +1 more source

Comparison of Thrombocytopenia and Splenomegaly in Locally Advanced Rectal Cancer Patients Receiving Total Neoadjuvant Therapy With and Without Immunotherapy. [PDF]

Cancer Med
Li S, Yan M, Ma Q, Sun Y, Zhang Z, Shen L, Wan J, Zhang H, Wu R, Xia F, Wang Y.   +10 more
europepmc   +1 more source